Monday, April 19, 2010
On April 1, 2010 - three days after a court ruling that invalidated Myriad's patents on the BRCA1 and BRCA2 genes (associated with hereditary breast and ovarian cancer) the company increased their prices for genetic testing. Old cost =$3,770. New cost = $4,040 for full sequencing plus rearrangement testing.
Congratulations to Christina Applegate on her recent engagement! Christina was diagnosed with breast cancer at age 36, and learned that she carries a BRCA1 mutation and chose to have a bilateral mastectomy with reconstruction. She reports that her fiancé has been "incredible" through her diagnosis and surgery. Follow the light blue link above to hear Christina's interview on Access Hollywood about breast reconstruction. Read more!
Friday, April 16, 2010
Check out the latest version of Cancer Bytes: Straight Talk about Early-Onset Ovarian Cancer. Click on the above light blue link to listen to this interview.
Friday, April 9, 2010
Myriad’s patents on the BRCA genes (associated with hereditary breast and ovarian cancer) include a sequence of DNA that is found in millions of other locations in the genome. Anyone making, using, selling, or importing this segment is in violation of these patents. Upon inspection, these patents appear to be surprisingly broad, and if enforced would have substantial implications for medical practice and scientific research. What do you think: should our genes be patented? Read more!